Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 3, Issue 1, Pages 27-32Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1471-4892(02)00006-1
Keywords
-
Categories
Funding
- NIGMS NIH HHS [R01-GM34790] Funding Source: Medline
- NINDS NIH HHS [P50-NS08803, R01-NS40978] Funding Source: Medline
Ask authors/readers for more resources
The intensity of experimental and clinical research to identify a neuroprotective drug for the treatment of traumatic brain injury is motivated by the devastating morbidity and mortality of this condition. Encouraging experimental work has led so far to disappointing clinical trials and the identification of new potential therapeutic targets is critically dependent on a better understanding of the chronic pathophysiology triggered by the initial insult. Future advances in the pharmacological treatment of traumatic brain injury are likely to include the evaluation of sequentially timed therapies combining multiple and targeted agents, and manipulation of the newly discovered neurogenic potential of the adult brain together with the refinement of traditional interventions to block specific cytotoxic cascades.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available